Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Derek Weycker, Mark Bensink, Alexander Lonshteyn, Robin Doroff & David Chandler. (2019) Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment. Current Medical Research and Opinion 35:6, pages 1073-1080.
Read now
Read now
Derek Weycker, Ahuva Hanau, Alexander Lonshteyn, Charles Bowers, Tamer Garawin, Mark Bensink & David Chandler. (2019) Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims. Current Medical Research and Opinion 35:4, pages 725-730.
Read now
Read now
Articles from other publishers (6)
Aylin Yucel, Anne Skalicky, Olabimpe Ruth Eseyin, Emre Yucel, Rajesh Belani & Mark Bensink. (2021) Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating Factor (SEQ-G-CSF). Journal of Patient-Reported Outcomes 5:1.
Crossref
Crossref
Prasad L. Gawade, Shuling Li, David Henry, Nancy Smith, Rajesh Belani, Michael A. Kelsh & Brian D. Bradbury. (2020) Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Supportive Care in Cancer 28:9, pages 4413-4424.
Crossref
Crossref
Derek Weycker, Robin Doroff, Ahuva Hanau, Charles Bowers, Rajesh Belani, David Chandler, Alexander Lonshteyn, Mark Bensink & Gary H. Lyman. (2019) Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study. BMC Cancer 19:1.
Crossref
Crossref
Derek Weycker, Mark Hatfield, Aaron Grossman, Ahuva Hanau, Alex Lonshteyn, Anjali Sharma & David Chandler. (2019) Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer 19:1.
Crossref
Crossref
Jean Paul Salmon, Martin Smakal, Charisios Karanikiotis, Marek Z. Wojtukiewicz, Yohann Omnes, Lucy DeCosta, Sally Wetten & James O’Kelly. (2018) Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin’s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study. Supportive Care in Cancer 27:4, pages 1449-1457.
Crossref
Crossref
Jie Xie, Jun Cao, Jing-fen Wang, Bai-hong Zhang, Xiao-hua Zeng, Hong Zheng, Yang Zhang, Li Cai, Yu-dong Wu, Qiang Yao, Xiao-chun Zhao, Wei-dong Mao, Ai-Mei Jiang, Shao-shui Chen, Shun-e Yang, Shu-sen Wang, Jian-hong Wang, Yue-yin Pan, Bi-yong Ren, Yan-ju Chen, Li-zhi Ouyang, Kai-jian Lei, Jing-hua Gao, Wen-he Huang, Zhan Huang, Tao Shou, Yan-ling He, Jing Cheng, Yang Sun, Wei-ming Li, Shu-de Cui, Xin Wang, Zhi-guo Rao, Hu Ma, Wei Liu, Xue-yong Wu, Wei-xi Shen, Fei-lin Cao, Ze-min Xiao, Biao Wu, Shu-yan Tian, Dong Meng, Peng Shen, Bi-yun Wang, Zhonghua Wang, Jian Zhang, Leiping Wang & Xi-chun Hu. (2017) Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. Breast Cancer Research and Treatment 168:2, pages 389-399.
Crossref
Crossref